A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).
Clinical trial NCT07641426 · RECRUITING
Trial details
- NCT number
- NCT07641426
- Sponsor
- CASI pharmaceuticals, Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-09
- Primary completion
- 2030-05-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.